By Dave Sebastian

Pfizer Inc. will provide sales and marketing support for Exact Sciences Corp.'s Cologuard, a DNA screening test for colorectal cancer, through the end of 2022, in an extension of the two companies' promotion agreement, they said.

Pfizer also will help Exact Sciences with health-system matters through the end of next year, the companies said Wednesday. Under the agreement, Exact Sciences will pay Pfizer based on the amount of services provided, as well as fixed and performance-related fees.

The companies have been working together on the drug's promotion for two years, Exact Sciences Chairman and Chief Executive Kevin Conroy said. Exact Sciences will continue manufacturing and overseeing laboratory operations of Cologuard, the companies said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

10-07-20 0643ET